



**Supplemental Material to:**

**Larry Zeitlin, Ognian Bohorov, Natasha Bohorova, Andrew Hiatt, Do H. Kim, Michael H. Pauly, Jesus Velasco, Kevin J. Whaley, Dale L. Barnard, John T. Bates, James E. Crowe, Jr., Pedro A. Piedra and Brian E. Gilbert**


**Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model**

**2013; 5(2)**


**<http://dx.doi.org/10.4161/mabs.23281>**







**<http://www.landesbioscience.com/journals/mabs/23281/>**

A.



B.





### Supplementary Figure Legends

**Figure S1.** A. SDS-PAGE of palivizumab and palivizumab-N run under non-reducing and reducing conditions. 1.5  $\mu\text{g}$  of each mAb was used for each lane. Samples were run on a Novex 4-12% Tris-glycine gel with Spectra Multicolor High Range Protein Ladder (Thermo Scientific). B. HPLC-SEC of palivizumab and palivizumab-N. Size-exclusion analysis was performed on the Agilent 1100 Series HPLC system using TOSOH Bioscience TSKgel SuperSW3000 column. The samples were run on the column for 30 min at 0.2 mL/min with 100% BupH Phosphate Buffered Saline (0.1 M sodium phosphate + 0.15 M sodium chloride, pH 7.2).

**Figure S2.** Surface plasmon resonance of mAb binding to recombinant RSV F (strain A2) measured on a Biacore X100. An NTA chip was used to capture recombinant gF and each mAb was then flowed over the chip at 5 different concentrations.